The CNIPA offers insight in upholding a compound patent's va

Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees

Related Keywords

, Actelion Pharmaceuticals , China National Intellectual Property Administration , World Intellectual Property Day , Top Ten Patent Reexamination , Invalidation Cases ,